Hepatitis B virus resistance to nucleos(t)ide analogues.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gastroenterology

• Publication date

  2009-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2009.08.063PMID 19737565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Control of hepatitis B virus replication by innate response of HepaRG cells

  2010cited by this paper
• Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?

  2010cited by this paper
• 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

  2009cited by this paper
• Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro

  2009cited by this paper
• Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• 20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS

  2009cited by this paper
• W1805 Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in NaïVE Patients

  2009cited by this paper
• Complex dynamics of hepatitis B virus resistance to adefovir

  2009cited by this paper
• Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro

  2009cited by this paper
• Efficacy of hepatitis B vaccine against antiviral drug‐resistant hepatitis B virus mutants in the chimpanzee model

  2009cited by this paper
• Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

  2009cited by this paper
• In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.

  2009cited by this paper
• Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen

  2008cited by this paper
• Antiviral Resistance Mutations Potentiate hepatitis B virus Immune Evasion through Disruption of its Surface Antigen a Determinant

  2008cited by this paper
• Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

  2008cited by this paper
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

  2008cited by this paper
• Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B

  2008cited by this paper
• Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants

  2008cited by this paper
• Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

  2008cited by this paper
• Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

  2008cited by this paper
• Hepatitis B: reflections on the current approach to antiviral therapy.

  2008cited by this paper
• Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication

  2008cited by this paper
• Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.

  2008cited by this paper
• Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection.

  2008cited by this paper
• Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein

  2008cited by this paper
• The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

  2008cited by this paper
• Hepatitis B virus infection.

  2008cited by this paper
• [505] MULTIDRUG RESISTANCE AND CROSS-RESISTANCE PATHWAYS IN HBV AS A CONSEQUENCE OF TREATMENT FAILURE

  2007cited by this paper
• Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

  2007cited by this paper
• Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.

  2007cited by this paper
• SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

  2007cited by this paper
• Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

  2007cited by this paper
• Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.

  2007cited by this paper
• Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

  2007cited by this paper
• Antiviral therapy of chronic hepatitis B: prevention of drug resistance.

  2007cited by this paper
• Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

  2007cited by this paper
• Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

  2007cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2007cited by this paper
• Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

  2007cited by this paper
• Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage

  2007cited by this paper
• Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

  2006cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

  2006cited by this paper
• Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

  2006cited by this paper
• Variant of hepatitis B virus with primary resistance to adefovir.

  2006cited by this paper
• Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir

  2006cited by this paper
• Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

  2006cited by this paper
• Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

  2006cited by this paper
• Dynamics of Hepatitis B Virus Resistance to Lamivudine

  2006cited by this paper
• European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes

  2006cited by this paper
• Evolution of multi‐drug resistant hepatitis B virus during sequential therapy

  2006cited by this paper
• A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

  2006cited by this paper
• In vitro models for studying hepatitis B virus drug resistance.

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones.

  2006cited by this paper
• HBV drug resistance: mechanisms, detection and interpretation.

  2006cited by this paper
• The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.

  2005cited by this paper
• Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein

  2005cited by this paper
• Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy.

  2005cited by this paper
• Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

  2005cited by this paper
• New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

  2005cited by this paper
• Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

  2005cited by this paper
• The concept of hepatitis B virus mutant escape.

  2005cited by this paper
• Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

  2005cited by this paper
• Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

  2004cited by this paper
• A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus

  2004cited by this paper
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

  2004cited by this paper
• Management of Antiviral Resistance in Patients with Chronic Hepatitis B

  2004cited by this paper
• HIV drug resistance.

  2004cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• Lamivudine-Resistant Hepatitis B Virus and Ongoing Lamivudine Therapy: Stop the Merry-Go-Round, It'S Time to get off!

  2004cited by this paper
• Viral features of lamivudine resistant hepatitis B genotypes A and D

  2004cited by this paper
• Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.

  2004cited by this paper
• HIV drug resistance.

  2004cited by this paper
• Oligonucleotide Chip for Detection of Lamivudine-Resistant Hepatitis B Virus

  2004cited by this paper
• The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

  2003cited by this paper
• Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

  2003cited by this paper
• Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes

  2003cited by this paper
• Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

  2003cited by this paper
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

  2003cited by this paper
• Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids

  2003cited by this paper
• Quasispecies and the development of new antiviral strategies.

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cited by this paper
• Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

  2002cited by this paper
• Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.

  2002cited by this paper
• Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus

  2002cited by this paper
• Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro

  2002cited by this paper
• Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

  2002cited by this paper
• Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro

  2002cited by this paper
• Primary infection with a lamivudine-resistant hepatitis B virus.

  2002cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay

  2002cited by this paper
• In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

  2001cited by this paper
• In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.

  2001cited by this paper
• Antiviral Activity of β-l-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus

  2001cited by this paper

• Advances in pharmacological interventions for hepatic fibrosis: from pathogenic mechanisms to novel therapeutic targets

  2026cites this paper
• Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B.

  2026cites this paper
• Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection

  2025cites this paper
• Bifurcation and optimal control analysis for a fractional-order model of drug-resistant HBV infection

  2025cites this paper
• Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluation

  2025cites this paper
• Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-naïve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study

  2025cites this paper
• Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field.

  2025cites this paper
• Inactivation of the key ORFs of HBV for antiviral therapy by non-cleavage base editing.

  2025cites this paper
• Unraveling the Complexities of Hepatitis B Virus Control: A Mathematical Modeling Approach

  2025cites this paper
• Immunomodulatory effect of Moringa oleifera and Phyllanthus niruri extracts on anti-HBV cytokine production by human peripheral blood mononuclear cells

  2025cites this paper
• Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients

  2025cites this paper
• Exploratory analysis of lamivudine legacy and clonal selection of HBs truncation mutants in HBV-related hepatocellular carcinoma

  2025cites this paper
• CRISPR-Cas technologies: Emerging tools from research to clinical application.

  2025cites this paper
• Performance evaluation of a fully automated deep sequencing platform for hepatitis B genotyping and resistance testing.

  2025cites this paper
• Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment

  2025cites this paper
• Programmable synthesis of alkaloidal frameworks integrating Michael acceptor generates covalent probes for targeting POLE3 in HBV replication

  2025cites this paper
• The first case of transfusion‐transmitted hepatitis B virus genotype I in Japan

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trials

  2025cites this paper
• Modelling the Impact of Relapse and Weaning Off Immunity on Hepatitis B Virus Transmission Dynamics

  2024cites this paper
• Evaluation of genotype characteristics and drug resistance mutations in patients with chronic hepatitis B

  2024cites this paper
• Social, clinical and biological barriers to hepatitis B virus suppression with nucleos/tide analogue therapy: who is at risk and what should we do about it?

  2024cites this paper
• MicroRNA levels in patients with chronic hepatitis B virus and HIV coinfection in a high-prevalence setting; KwaZulu-Natal, South Africa

  2024cites this paper
• Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update

  2024cites this paper
• Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy

  2024influential citation
• In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

  2024cites this paper
• Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus.

  2023cites this paper
• Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels

  2023cites this paper
• Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus.

  2023cites this paper
• In vitro evaluation of tropolone absorption, metabolism, and clearance.

  2023cites this paper
• Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis

  2023cites this paper
• The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

  2023cites this paper
• A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Molecular and Genetic Characterization of Hepatitis B Virus (HBV) among Saudi Chronically HBV-Infected Individuals

  2023cites this paper
• Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target

  2023cites this paper
• Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication

  2023cites this paper
• High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico

  2023cites this paper
• Virtual Screening of Hepatitis B Virus Pre-Genomic RNA as a Novel Therapeutic Target

  2023cites this paper
• Inhibition of Hepatitis B Virus (HBV) replication and antigen expression by Brucea javanica (L.) Merr. oil emulsion

  2023cites this paper
• Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.

  2023cites this paper
• Chronic Hepatitis B Infection: New Approaches towards Cure

  2023cites this paper
• Structural insights into modeling of hepatitis B virus reverse transcriptase and identification of its inhibitors from potential medicinal plants of Western Ghats: an in silico and in vitro study

  2023cites this paper
• Persistent Hepatitis B Viraemia with Polymerase Mutations among HIV/HBV Co-Infected Patients on HBV-Active ART in KwaZulu-Natal, South Africa

  2022influential citation
• Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy

  2022cites this paper
• Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

  2022cites this paper
• Viral hepatitis in 2021: The challenges remaining and how we should tackle them

  2022cites this paper
• Recent trends and advancements in electrochemiluminescence biosensors for human virus detection

  2022cites this paper
• Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries

  2022cites this paper
• Naturally occurring HMGB1 inhibitor delineating the anti-hepatitis B virus mechanism of glycyrrhizin via in vitro and in silico studies

  2022cites this paper
• From HIV to COVID-19, Molecular mechanisms of pathogens’ trade-off and persistence in the community, potential targets for new drug development

  2022cites this paper
• A Potentially Efficacious Approach for Treating HBV Viremia Using Combinatorial Cocktail Treatment

  2022cites this paper
• A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran

  2022cites this paper
• Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies

  2022cites this paper
• Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir

  2022cites this paper
• Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues.

  2022cites this paper
• The hepatitis B virus polymerase.

  2021cites this paper
• A nuanced role of the small loop of hepatitis B virus small envelope protein in virion morphogenesis and secretion

  2021cites this paper
• Quercetin and its derivates as antiviral potentials: A comprehensive review

  2021cites this paper
• Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia.

  2021cites this paper
• Blocking neddylation elicits antiviral effect against hepatitis B virus replication

  2021cites this paper
• Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

  2021cites this paper
• S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

  2021cites this paper
• Molecular Virology and Life Cycle of Hepatitis B Virus

  2021cites this paper
• The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target

  2021influential citation
• Multifunctional antimicrobial materials: from rational design to biomedical applications

  2021cites this paper
• Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection

  2021cites this paper
• Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women

  2021cites this paper
• Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR

  2021cites this paper
• Hepatitis B virus–host interactions and novel targets for viral cure

  2021cites this paper
• Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations

  2021influential citation
• Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication.

  2021cites this paper
• Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.

  2021cites this paper
• Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus

  2021cites this paper
• HBV Core Protein Is in Flux between Cytoplasmic, Nuclear, and Nucleolar Compartments

  2021cites this paper
• Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

  2021cites this paper
• Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B

  2021cites this paper
• Molecular and computational analysis of natural drug resistance mutations among Moroccan chronic hepatitis B carriers

  2021cites this paper
• Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes

  2021cites this paper
• The evolution and clinical impact of hepatitis B virus genome diversity

  2020cites this paper
• Establishment of a system for finding inhibitors of ε RNA binding with the HBV polymerase

  2020cites this paper
• HBV induced hepatocellular carcinoma and related potential immunotherapy.

  2020cites this paper
• HBV variants are common in the ‘immune‐tolerant’ phase of chronic hepatitis B

  2020cites this paper
• Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing.

  2020cites this paper
• Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

  2020cites this paper
• Entecavir‐resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization

  2020cites this paper
• Difluoromethylornithine, a Decarboxylase 1 Inhibitor, Suppresses Hepatitis B Virus Replication by Reducing HBc Protein Levels

  2020cites this paper
• Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study

  2020cites this paper
• JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update.

  2020cites this paper
• HBV replication inhibitors.

  2020cites this paper
• Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.

  2020cites this paper
• Hepatitis B-related glomerulonephritis and optimization of treatment

  2020influential citation
• Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus

  2020cites this paper
• Present and Future Therapies for Chronic Hepatitis B.

  2020cites this paper
• Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent

  2020cites this paper
• Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients.

  2020cites this paper
• New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation

  2020cites this paper
• Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region

  2020cites this paper
• Hepatitis B Virus

  2020cites this paper
• HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals.

  2020cites this paper
• Havachoobe (Onosma dichroanthum Boiss) Root Extract Decreases the Hepatitis B Virus Surface Antigen Secretion in the PLC/PRF/5 Cell Line

  2020cites this paper